Preliminary Data from Roche Molecular Systems, Inc. (RHHBF.PK) ATHENA Cervical Cancer Trial Support Value of Human Papillomavirus Genotyping
2/18/2010 11:19:57 AM
MONTE CARLO, Monaco, Feb. 18 /PRNewswire-FirstCall/ -- Roche Molecular Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY) announced today that preliminary data from its ATHENA (Addressing THE Need for Advanced HPV Diagnostics) trial support the importance of screening for human papillomavirus (HPV) genotypes that put women at highest risk for developing cervical cancer. ATHENA is a prospective, double-blind, multi-centered, 47,000-patient, U.S.-registration trial designed to demonstrate the effectiveness of HPV detection as part of a cervical cancer screening program. Thomas C. Wright Jr., M.D., of Columbia University presented the preliminary data on February 18 during the Genotyping session (Scientific Session 2) at the EUROGIN 2010 congress in Monaco.